Wuhan Institute of Biological Products
A Sinopharm-affiliated Chinese institute combining biological-products research, education, manufacturing, and marketing.
Last updated October 12, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
The Wuhan Institute of Biological Products (WIBP), also known as the Wuhan Institute of Biology, is a Chinese biological-products research and manufacturing institution based in Wuhan, Hubei. It is a subsidiary of China National Pharmaceutical Group Corporation, commonly known as Sinopharm, and forms part of the group’s state-owned pharmaceutical and biotechnology network. WIBP combines several functions that are often separated in commercial pharmaceutical organizations. Its activities include scientific research, biological-products production, technical education, and marketing. The institute operates one of China’s significant biological-products manufacturing facilities and has more than 1,000 employees. Its work is associated with vaccines and other biological medicines, while its commercial subsidiary, Wuhan Zhongsheng Yujin Biomedical, focuses primarily on blood-derived products. These include human albumin, human immune globulin, and tetanus immune globulin. The institute’s educational role is also central to its identity. It confers master’s degrees and supports doctoral and postdoctoral programs in biotechnology-related fields, linking industrial production with advanced training and research. This integrated structure gives WIBP a role not only as a manufacturer but also as a scientific and professional-development institution within China’s public-health and biopharmaceutical system. WIBP was established in September 1950 in Wuchang District, Wuhan. In 2016 it moved to the Zhengdian Gold Industrial Park in Jiangxia District. The new location is next to the Wuhan Institute of Virology, and the two institutions collaborate closely. The relocation reflects the institute’s continuing development as a large-scale research and production center. The institute is also associated with the Sinopharm WIBP COVID-19 vaccine, placing it among Chinese biological-products organizations involved in the development and production of vaccines during the COVID-19 response. Available reference material does not establish a complete product portfolio, commercial sales record, or current leadership roster, so those details are not expanded here.
History
The Wuhan Institute of Biological Products was established in September 1950 in Wuchang District, Wuhan. It developed as a biological-products institution combining scientific research with practical production and later added formal educational and commercial functions. The institute is part of China National Pharmaceutical Group Corporation, or Sinopharm, a state-owned pharmaceutical group, and operates within the broader Chinese public-health and biopharmaceutical system. Over time, WIBP became an integrated organization rather than a narrowly defined manufacturing site. Its activities encompass biological-products research, production, marketing, and the training of specialists. The institute confers master’s degrees and operates doctoral and postdoctoral programs in biotechnology-related fields. This combination of industrial and academic functions supports the development of technical expertise alongside the manufacture of biological medicines. The institute’s production activities include vaccines and blood-derived products. Its commercial arm operates Wuhan Zhongsheng Yujin Biomedical as a wholly owned subsidiary. That subsidiary is primarily concerned with the production and distribution of blood products, including human albumin, human immune globulin, and tetanus immune globulin. The available reference material does not provide a full chronology of individual product approvals, plant expansions, or commercial launches. In 2016, WIBP relocated from Wuchang District to the Zhengdian Gold Industrial Park in Jiangxia District, Wuhan. The new site is adjacent to the Wuhan Institute of Virology, with which WIBP collaborates. The move placed the institute within a research and industrial setting intended to support its continuing production and scientific activities. WIBP was subsequently associated with the Sinopharm WIBP COVID-19 vaccine. This association reflects the institute’s role in vaccine development and production during the COVID-19 pandemic, although the supplied reference material does not provide sufficient detail to document a complete development timeline, regulatory history, manufacturing volumes, or market-by-market distribution. The institute continues to be described as an active Sinopharm subsidiary with more than 1,000 employees and a combined research, education, manufacturing, and marketing mandate.
Products and positioning
An integrated Chinese biological-products institute combining research, higher education, vaccine and blood-product manufacturing, and commercialization within the Sinopharm group.
Biological medicines
Vaccines
Vaccines are among WIBP’s principal biological-products activities. The institute is associated with the Sinopharm WIBP COVID-19 vaccine, although the supplied reference material does not specify a complete range of vaccine products or provide detailed approval and launch dates.
Blood product
Human albumin
Human albumin is one of the blood-derived products associated with Wuhan Zhongsheng Yujin Biomedical, WIBP’s wholly owned commercial subsidiary. The subsidiary focuses on the production and distribution of blood products within the institute’s broader commercial operations.
Blood product
Human immune globulin
Human immune globulin is part of the blood-product portfolio identified for WIBP’s commercial subsidiary. The supplied material does not specify individual formulations, indications, production capacity, or launch chronology.
Blood product
Tetanus immune globulin
Tetanus immune globulin is another blood-derived product associated with Wuhan Zhongsheng Yujin Biomedical. It is included among the subsidiary’s production and distribution activities.
COVID-19 vaccine
Sinopharm WIBP COVID-19 vaccine
The Sinopharm WIBP COVID-19 vaccine is the institute’s best-known named vaccine association in the supplied reference material. The available sources identify the product but do not provide enough information here to state its precise development, authorization, or distribution chronology.
Controversies
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/wuhan-institute-of-biological-products · Editorial policy · How profiles are compiled